11:10 AM EDT, 07/24/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price to $14 from $11, 12.1x our 2026 EPS, a sharp discount to AVTR's five-year historical forward P/E average of 21.0x, justified by the complex operating environment the company is navigating. We maintain our 2025 EPS estimate at $1.02 and our 2026 EPS forecast at $1.16. Following recent better-than-anticipated Q2 results from key players such as Thermo Fisher Scientific (TMO 481 ****), Iqvia Holdings (IQV 204 ***) and Icon (ICLR 205 ***), we think the investor sentiment toward the life science tools & services sub-industry is improving. While we continue to see elevated policy risks and the business environment as highly volatile in the near term, we think the downside potential is becoming limited at current valuations. Avantor ( AVTR ) is expected to announce its Q2 results next week on August 1. While we expect to see sequential improvement in top- and bottom-line results, we also think both revenue and EPS will decline Y/Y.